Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan

A preliminary study

Yen Ching Chen, L. Xu, Y. L.L. Guo, Huey-Jen Su, T. J. Smith, L. M. Ryan, M. S. Lee, D. C. Christiani

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Little is known about the relevance of genetic polymorphisms to arsenic-related bladder cancer. A preliminary case-control study was conducted to explore the association between genetic polymorphisms of GSTT1, p53 codon 72 and bladder cancer in southern Taiwan, a former high arsenic exposure area. Fifty-nine urinary transitional cell carcinoma (TCC) patients from a referral centre in south-western Taiwan and 81 community controls matched on residence were recruited from 1996 to 1999. A questionnaire was administered to obtain arsenic exposure and general health information. Genotypes of p53 codon 72 and GSTT1 were analysed by polymerase chain reaction-restriction fragment length polymerase. The combined variant genotypes (heterozygous or homozygous variant) of p53 codon 72 and GSTT1 null were observed in 29% of cases and in 44% of controls, respectively. In this preliminary study, bladder cancer risk was slightly elevated for subjects carrying the variant genotype of p53 codon 72 or in subjects carrying the GSTT1 null genotype. Variants in p53 codon 72 increased the risk of bladder cancer among smokers. However, the results were not statistically significant and larger confirmatory studies are needed to clarify the role of candidate gene polymorphisms and bladder cancer risk in arsenic exposed populations.

Original languageEnglish
Pages (from-to)386-394
Number of pages9
JournalBiomarkers
Volume9
Issue number4-5
DOIs
Publication statusPublished - 2004 Jul 1

Fingerprint

Transitional Cell Carcinoma
Arsenic
Polymorphism
Taiwan
Urinary Bladder Neoplasms
Codon
Cells
Genotype
Genetic Polymorphisms
Polymerase chain reaction
Genes
Health
Case-Control Studies
Referral and Consultation
Polymerase Chain Reaction
Population

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Chen, Yen Ching ; Xu, L. ; Guo, Y. L.L. ; Su, Huey-Jen ; Smith, T. J. ; Ryan, L. M. ; Lee, M. S. ; Christiani, D. C. / Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan : A preliminary study. In: Biomarkers. 2004 ; Vol. 9, No. 4-5. pp. 386-394.
@article{0b5678fb968d49d98e8a07e38d9c450f,
title = "Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: A preliminary study",
abstract = "Little is known about the relevance of genetic polymorphisms to arsenic-related bladder cancer. A preliminary case-control study was conducted to explore the association between genetic polymorphisms of GSTT1, p53 codon 72 and bladder cancer in southern Taiwan, a former high arsenic exposure area. Fifty-nine urinary transitional cell carcinoma (TCC) patients from a referral centre in south-western Taiwan and 81 community controls matched on residence were recruited from 1996 to 1999. A questionnaire was administered to obtain arsenic exposure and general health information. Genotypes of p53 codon 72 and GSTT1 were analysed by polymerase chain reaction-restriction fragment length polymerase. The combined variant genotypes (heterozygous or homozygous variant) of p53 codon 72 and GSTT1 null were observed in 29{\%} of cases and in 44{\%} of controls, respectively. In this preliminary study, bladder cancer risk was slightly elevated for subjects carrying the variant genotype of p53 codon 72 or in subjects carrying the GSTT1 null genotype. Variants in p53 codon 72 increased the risk of bladder cancer among smokers. However, the results were not statistically significant and larger confirmatory studies are needed to clarify the role of candidate gene polymorphisms and bladder cancer risk in arsenic exposed populations.",
author = "Chen, {Yen Ching} and L. Xu and Guo, {Y. L.L.} and Huey-Jen Su and Smith, {T. J.} and Ryan, {L. M.} and Lee, {M. S.} and Christiani, {D. C.}",
year = "2004",
month = "7",
day = "1",
doi = "10.1080/13547500400010122",
language = "English",
volume = "9",
pages = "386--394",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "4-5",

}

Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan : A preliminary study. / Chen, Yen Ching; Xu, L.; Guo, Y. L.L.; Su, Huey-Jen; Smith, T. J.; Ryan, L. M.; Lee, M. S.; Christiani, D. C.

In: Biomarkers, Vol. 9, No. 4-5, 01.07.2004, p. 386-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan

T2 - A preliminary study

AU - Chen, Yen Ching

AU - Xu, L.

AU - Guo, Y. L.L.

AU - Su, Huey-Jen

AU - Smith, T. J.

AU - Ryan, L. M.

AU - Lee, M. S.

AU - Christiani, D. C.

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Little is known about the relevance of genetic polymorphisms to arsenic-related bladder cancer. A preliminary case-control study was conducted to explore the association between genetic polymorphisms of GSTT1, p53 codon 72 and bladder cancer in southern Taiwan, a former high arsenic exposure area. Fifty-nine urinary transitional cell carcinoma (TCC) patients from a referral centre in south-western Taiwan and 81 community controls matched on residence were recruited from 1996 to 1999. A questionnaire was administered to obtain arsenic exposure and general health information. Genotypes of p53 codon 72 and GSTT1 were analysed by polymerase chain reaction-restriction fragment length polymerase. The combined variant genotypes (heterozygous or homozygous variant) of p53 codon 72 and GSTT1 null were observed in 29% of cases and in 44% of controls, respectively. In this preliminary study, bladder cancer risk was slightly elevated for subjects carrying the variant genotype of p53 codon 72 or in subjects carrying the GSTT1 null genotype. Variants in p53 codon 72 increased the risk of bladder cancer among smokers. However, the results were not statistically significant and larger confirmatory studies are needed to clarify the role of candidate gene polymorphisms and bladder cancer risk in arsenic exposed populations.

AB - Little is known about the relevance of genetic polymorphisms to arsenic-related bladder cancer. A preliminary case-control study was conducted to explore the association between genetic polymorphisms of GSTT1, p53 codon 72 and bladder cancer in southern Taiwan, a former high arsenic exposure area. Fifty-nine urinary transitional cell carcinoma (TCC) patients from a referral centre in south-western Taiwan and 81 community controls matched on residence were recruited from 1996 to 1999. A questionnaire was administered to obtain arsenic exposure and general health information. Genotypes of p53 codon 72 and GSTT1 were analysed by polymerase chain reaction-restriction fragment length polymerase. The combined variant genotypes (heterozygous or homozygous variant) of p53 codon 72 and GSTT1 null were observed in 29% of cases and in 44% of controls, respectively. In this preliminary study, bladder cancer risk was slightly elevated for subjects carrying the variant genotype of p53 codon 72 or in subjects carrying the GSTT1 null genotype. Variants in p53 codon 72 increased the risk of bladder cancer among smokers. However, the results were not statistically significant and larger confirmatory studies are needed to clarify the role of candidate gene polymorphisms and bladder cancer risk in arsenic exposed populations.

UR - http://www.scopus.com/inward/record.url?scp=11944259878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11944259878&partnerID=8YFLogxK

U2 - 10.1080/13547500400010122

DO - 10.1080/13547500400010122

M3 - Article

VL - 9

SP - 386

EP - 394

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 4-5

ER -